Lurbinectedin is a drug that is being tested for its safety and efficacy in treating different types of cancer. According to the sources provided, the results of the safety tests for lurbinectedin have been promising.

The FDA has reviewed the safety and efficacy of lurbinectedin in treating small cell lung cancer (SCLC) and approved it for use in patients who have previously received chemotherapy [2]. The FDA's review of the drug's clinical trial data found that lurbinectedin had an overall response rate of 35% in patients with SCLC [2]. The drug was also found to have manageable side effects, such as nausea, fatigue, and low white blood cell count [2].

In addition to the FDA's review, a study published in the Journal of Clinical Oncology evaluated the safety and efficacy of lurbinectedin in treating patients with advanced solid tumors [3]. The study found that lurbinectedin had a manageable safety profile and demonstrated promising efficacy in treating certain types of cancer, including ovarian and lung cancer [3].

Overall, the results of the safety tests for lurbinectedin have been promising. The drug has been found to have a manageable safety profile and has demonstrated efficacy in treating certain types of cancer. However, further research is needed to fully evaluate the drug's safety and efficacy in treating different types of cancer [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331752/